NCT07871370|Completed
Silymarin Effects on Fatty Liver in Type 2 Diabetics
Effect of Silymarin (Milk Thistle) on Hepatic Fibrosis, Glycemic Control and Biochemical Parameters in Type 2 Diabetic Patients
Loading search results
Effect of Silymarin (Milk Thistle) on Hepatic Fibrosis, Glycemic Control and Biochemical Parameters in Type 2 Diabetic Patients
Sponsor study identifier
interventional
120
1 country
1
Study Start
January 2, 2024
Actual (reported)Primary Completion
June 1, 2026
Actual (reported)Study Completion
June 1, 2026
Actual (reported)This nine-month prospective clinical trial evaluated the effects of adding a daily oral dose of 480 mg of silymarin (milk thistle) to standard multi-drug therapy in 120 adult patients with Type 2 diabetes. Compared to the control group receiving standard care alone, participants taking silymarin showed significant reductions in liver enzymes (AST and ALT), improvements in their lipid profiles, and reduced liver fat (steatosis) confirmed via FibroScan imaging. While renal function remained stable and the supplement proved safe, silymarin did not lead to changes in overall liver fibrosis stages over the study duration. Ultimately, the trial demonstrates that silymarin can serve as a safe and effective adjunctive supplement to help manage hepatic steatosis and liver inflammation in patients with Type 2 diabetes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 1, 2026
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2, 2024
Actual (reported)June 1, 2026
Actual (reported)June 1, 2026
Actual (reported)October 6, 2026
Actual (reported)October 13, 2026
Actual (reported)Change in Liver Steatosis and Fibrosis Scores
Measured using FibroScan (transient elastography) to assess changes in liver fat content (Controlled Attenuation Parameter / CAP) and liver stiffness/fibrosis stage.
From enrollment to end of treatment at 9 months.
Change in Glycemic, Hepatic, Lipid, and Renal Laboratory Parameters
From enrollment to end of treatment at 9 months.
Participants received a daily oral dose of 480 mg of silymarin as an add on supplementation for 9 months.
No intervention
Participants received a daily oral dose of 480 mg of silymarin as an add on supplementation for 9 months.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Outpatient Clinic, Ibn Sina Teaching Hospital
Mosul, Iraq
120 participants (actual enrollment reported by the registry).
First Submitted
October 6, 2026
First Posted
October 13, 2026
Study Start
January 2, 2024
Actual (reported)Primary Completion
June 1, 2026
Actual (reported)Study Completion
June 1, 2026
Actual (reported)Last Updated
October 13, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: